Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J I Friedman

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Biological Psychiatry|January 23, 1999
Pharmacologic strategies for augmenting cognitive performance in schizophreniaJ I Friedman, H Temporini, K L Davis
Biological Psychiatry|November 24, 1999
The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's diseaseJ I Friedman, D N Adler, K L Davis
Current Psychiatry Reports|September 18, 2001
Cognition in schizophreniaP D Harvey, C R Bowie, J I Friedman
Biological Psychiatry|October 6, 1999
Cognitive and functional changes with aging in schizophreniaJ I Friedman, P D Harvey, E Kemether, et al.
Biological Psychiatry|June 6, 2000
Differential preservation of cognitive functions in geriatric patients with lifelong chronic schizophrenia: less impairment in reading compared with other skill areasP D Harvey, P J Moriarty, J I Friedman, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 28, 2001
Guanfacine treatment of cognitive impairment in schizophreniaJ I Friedman, D N Adler, H D Temporini, et al.
The American Journal of Psychiatry|September 5, 2001
Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: a comparison with Alzheimer's disease and normal agingJ I Friedman, P D Harvey, T Coleman, et al.
Molecular Psychiatry|July 25, 2007
CNTNAP2 gene dosage variation is associated with schizophrenia and epilepsyJ I Friedman, T Vrijenhoek, S Markx, et al.
The Washington Post|December 5, 2002
Nobel laureates' letter to President BushK J Arrow, J Axelrod, B Benacerraf, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Biological Psychiatry|January 23, 1999
Pharmacologic strategies for augmenting cognitive performance in schizophreniaJ I Friedman, H Temporini, K L Davis
Biological Psychiatry|November 24, 1999
The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's diseaseJ I Friedman, D N Adler, K L Davis
Current Psychiatry Reports|September 18, 2001
Cognition in schizophreniaP D Harvey, C R Bowie, J I Friedman
Biological Psychiatry|October 6, 1999
Cognitive and functional changes with aging in schizophreniaJ I Friedman, P D Harvey, E Kemether, et al.
Biological Psychiatry|June 6, 2000
Differential preservation of cognitive functions in geriatric patients with lifelong chronic schizophrenia: less impairment in reading compared with other skill areasP D Harvey, P J Moriarty, J I Friedman, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 28, 2001
Guanfacine treatment of cognitive impairment in schizophreniaJ I Friedman, D N Adler, H D Temporini, et al.
The American Journal of Psychiatry|September 5, 2001
Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: a comparison with Alzheimer's disease and normal agingJ I Friedman, P D Harvey, T Coleman, et al.
Molecular Psychiatry|July 25, 2007
CNTNAP2 gene dosage variation is associated with schizophrenia and epilepsyJ I Friedman, T Vrijenhoek, S Markx, et al.
The Washington Post|December 5, 2002
Nobel laureates' letter to President BushK J Arrow, J Axelrod, B Benacerraf, et al.
Pageof 1